$2.58
-0.015-0.58%
Last update: Nov 2, 2:34 PM
Protalix BioTherapeutics Inc (PLX) Stock Price, Quote, News & History
PLXAMEX
EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.
You can purchase shares of Protalix BioTherapeutics (AMEX:PLX) through any online brokerage.
Other companies in Protalix BioTherapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Protalix BioTherapeutics has a consensus price target of $12.00.
The stock price for Protalix BioTherapeutics (AMEX: PLX) is $2.575 last updated November 2, 2026 at 2:34 PM EST.
There are no upcoming dividends for Protalix BioTherapeutics.
Protalix BioTherapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Protalix BioTherapeutics.
Protalix BioTherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant...
